从国际脂肪性肝病定义的变迁看2024版中国指南的工作定义与特色

The evolution of international definitions of fatty liver disease and insights into the working definition and features of the 2024 Chinese guidelines

摘要: 2020年以来，国际上先后提出了代谢相关脂肪性肝病（metabolic dysfunction-associated fatty liver disease, MAFLD）和代谢相关脂肪变性肝病（metabolic dysfunction-associated steatotic liver disease，MASLD）的新命名，2024年，中华医学会肝病学分会更新发布了《代谢相关（非酒精性）脂肪性肝病防治指南（2024年版）》。本文深入剖析MASLD和MAFLD在概念、定义框架、临床管理等方面的差异，并对2024版中国指南的工作定义的更新亮点与特色进行深入解读。

Abstract: Since 2020, the international community has successively proposed new nomenclatures for metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). In 2024, the Chinese Society of Hepatology updated and published the Guideline for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (version 2024). This review deeply analyzes the differences between MASLD and MAFLD in terms of concepts, definition frameworks, and clinical management. On this basis, it provides an in-depth interpretation of the updated highlights and features of the working definition in the 2024 updated Chinese guidelines.